Are Pot Stocks Like Aurora Cannabis (TSX:ACB) and Hexo (TSX:HEXO) Running Out of Cash?

Aurora Cannabis and Hexo will have to infuse capital by the end of 2020 to keep operations going.

| More on:

We know that cannabis companies have been struggling with structural and regulatory issues for a while. Most pot companies have reported less-than-impressive quarterly results over the last year, resulting in an extended bear run for investors.

The recreational marijuana industry has been rattled by illegal sales that still account for 40% of total Canadian cannabis sales. The slower-than-expected roll-out of retail stores in major provinces have resulted in high inventory levels.

Further, high capital expenditures and related investments have meant that pot companies are struggling to stay afloat and might very well run out of cash. According to a report from boutique investment bank Ello Capital, several cannabis companies, including heavyweights such as Aurora Cannabis (TSX:ACB)(NYSE:ACB) and Hexo (TSX:HEXO)(NYSE:HEXO), would need to raise additional capital sooner rather than later.

Several pot stocks are still reporting a negative EBITDA and operating cash flow. This suggests it will be difficult for companies to raise debt, forcing them to raise additional equity capital and resulting in the dilution of existing shareholder capital.

Aurora Cannabis

According to Ello Capital, Aurora Cannabis has about 2.3 months of leeway left before its cash balance is down to zero. Aurora ended the December quarter with a cash balance of $182.5 million. It has a total debt of $602 million, while its operating cash flow stands at -$288.9 million and free cash flow is at -$695 million.

Aurora Cannabis is grappling with several other issues. It announced the exit of founder and CEO Terry Booth recently. The company also had to stop construction for two key projects and announced close to $1 billion in balance sheet write-offs.

Aurora Cannabis stock has been pummeled in the last year. The stock is trading 84% below its 52-week high, and now with liquidity concerns, there is a chance that investors will continue to bleed in 2020 as well.

The massive correction for Aurora Cannabis has meant the stock is trading at a price-to-book ratio of 0.66. With a market cap of $2.55 billion, it is valued at 8.35 times forward sales.

Hexo is down 83% from 52-week high

Hexo is another company under the scanner. Ello Capital estimated Hexo’s cash balance to be enough for 6.5 months. Hexo already has raised about $100 million since October last year by equity offerings as well as convertible debentures.

Hexo ended the October quarter with a cash balance of $65.4 million. It has a total debt of $55 million, while its operating cash flow stands at -$138 million and free cash flow at -$246 million.

Hexo stock too has burnt investor wealth. The stock is currently trading 83% below its 52-week high. Shares fell 20% in January 2020 after Hexo’s acquisition of Newstrike came under the scanner. Newstrike was reportedly growing cannabis products illegally at its Beamsville facility in Niagara.

In fiscal 2020, Hexo aims to reduce operating expenses by 25%. Like most pot companies, Hexo is also banking on Cannabis 2.0 to drive product demand higher. Its partnership with Molson Coors can also help Hexo to stay afloat, which will give the firm a chance to make a comeback.

The verdict

There is a chance that Aurora, Hexo, and others may be able to issue additional capital in the upcoming months. However, there is also a chance that these companies will crash and burn considering the current pessimism surrounding pot stocks.

The cannabis industry is still at a nascent stage and can be likened to the dot com bubble of 2000. While Amazon and Alphabets’s Google rose from the ashes to generate millions of dollars in returns, there were hundreds of internet stocks that were wiped out without a trace.

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. David Gardner owns shares of Alphabet (A shares), Alphabet (C shares), and Amazon. Tom Gardner owns shares of Alphabet (A shares) and Alphabet (C shares). The Motley Fool owns shares of and recommends Alphabet (A shares), Alphabet (C shares), and Amazon. The Motley Fool recommends HEXO. and HEXO. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »